Document is current
Any future updates will be listed below
-
Authors
Aristizábal-Colorado, David https://orcid.org/0000-0002-8361-7748
Ocampo-Posada, Martín https://orcid.org/0000-0001-7154-3692
Rivera-Martínez, Wilfredo Antonio https://orcid.org/0000-0002-6079-6974
Corredor-Rengifo, David https://orcid.org/0000-0003-1750-5921
Rico-Fontalvo, Jorge https://orcid.org/0000-0002-2852-1241
Gómez-Mesa, Juan Esteban https://orcid.org/0000-0002-6635-6224
Duque-Ossman, John Jairo https://orcid.org/0000-0003-1097-5963
Abreu-Lomba, Alin https://orcid.org/0000-0002-7377-4969
- License Information
-
More Information
Article History
Accepted: 23 November 2024
First Online: 16 December 2024
Declarations
:
: No external funding was used in the preparation of this letter.
: Jorge Rico Fontalvo has received honoraria for lectures for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Novartis, AbbVie, Merck, and Bayer and has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, Bayer, and Novo Nordisk. John Jairo Duque Ossman has received honoraria for lectures for Adium Pharma. The other authors have no conflicts of interest to disclose.
: All authors participated in writing, reviewing and editing this reply.
: Data sharing not applicable to this article as no datasets were generated for this letter.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
